Onconic Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Onconic Therapeutics Inc. - overview
Established
2020
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
Based in Seoul, South Korea, Onconic Therapeutics Inc. , a subsidiary of Jeil Pharmaceutical, operates as a drug development company. In March 2021, Onconic Therapeutics Inc. raised KRW 27.
5 billion in Series A funding from BNH Investment, DAOL Investment, and Premier Partners. The round gives the company a pre-money valuation of KRW 70 billion. In December 2022, Onconic Therapeutics Inc. raised KRW 26 billion in Series B funding from AJU IB Investment, K2 Investment Partners, KDB Bank, and SL Investment.
As of 2022, the company’s CEO is John Kim. Onconic conducts various research and development activities in order to develop drugs for cancer and gastrointestinal diseases. The product line of the company includes OCN-201, which is an anti-cancer drug, and Zastaprazan (OCN-101), which is a potassium-competitive acid blocker (P-CAB) for gastric acid-related diseases. The company plans to use the funds raised in December 2022 to wrap up the Phase III clinical trials of drug candidate OCN-101 and the Phase II clinical trials of OCN-201, an anti-cancer drug candidate, and secure approvals for new drug development.
Current Investors
Korea Development Bank, AJU IB Investment, WOORI Venture Partners
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.onconic.co.kr
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.